Bicara Therapeutics Inc. ... (BCAX)
NASDAQ: BCAX
· Real-Time Price · USD
18.81
1.50 (8.67%)
At close: Oct 15, 2025, 3:59 PM
18.98
0.90%
After-hours: Oct 15, 2025, 06:25 PM EDT
Bicara Therapeutics Common Stock Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
Revenue | n/a | n/a | n/a |
Cost of Revenue | 56K | 19K | 10K |
Gross Profit | -56K | -19K | -10K |
Operating Income | -82.39M | -39.89M | -37.66M |
Interest Income | 14.58M | 1.31M | 4K |
Pretax Income | -67.81M | -51.98M | -37.84M |
Net Income | -68M | -51.98M | -37.84M |
Selling & General & Admin | 18.77M | 9.27M | 6.34M |
Research & Development | 8.22M | 30.62M | 31.31M |
Other Expenses | 55.4M | n/a | n/a |
Operating Expenses | 82.39M | 39.89M | 37.66M |
Interest Expense | n/a | n/a | 112K |
Selling & Marketing Expenses | n/a | n/a | n/a |
Cost & Expenses | 82.39M | 39.89M | 37.66M |
Income Tax Expense | 187K | 5K | 1K |
Shares Outstanding (Basic) | 54.42M | 51.76M | 51.76M |
Shares Outstanding (Diluted) | 54.42M | 51.76M | 51.76M |
EPS (Basic) | -1.25 | -1 | -0.73 |
EPS (Diluted) | -1.25 | -1 | -0.73 |
EBITDA | -67.75M | -51.96M | -37.72M |
EBIT | -67.81M | -51.98M | -37.73M |
Depreciation & Amortization | 56K | 19K | 10K |
Source: Financial Modeling Prep. Financial Sources.